Skip to content
Aurobindo Pharma logo

Aurobindo Pharma

AUROPHARMA NSE
₹1,799.00 −6.70 (−0.37%)
Market Cap
₹1,03,510 Cr
P/E
26.05
View as Markdown
MCP
Close 20 Nov 2026 ₹1,799.00 1Y +605.00 +50.7%
Start ₹1,194.00

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
12.90%
Debt to Equity
0.22
EPS (TTM)
₹69.05
Book Value
₹684.77
Market Cap
₹1,03,510 Cr
P/E (TTM)
26.05
P/B
2.63
ROE
10.10%
Dividend Yield
0.39%
EBITDA
₹7,338 Cr
52W High
₹1,859.90
52W Low
₹1,106.00
Day Range
₹1,788.10 – ₹1,817.50
Volume
8,11,247

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Aurobindo Pharma peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Aurobindo Pharma (this company)
1,799.0026.051,03,5102.630.39%10.10%12.90%36,9133,987
Median 8 companies1,841.9541.351,21,8404.690.48%16.25%16.65%29,2593,109

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
46
Average
Returns, margins, earnings quality 22% weight
Valuation
82
Strong
Cheap vs sector & own history 24% weight
Growth
37
Poor
Sales & profit trajectory 9% weight
Financial Health
50
Average
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
52
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

4
  • Stock is trading at 2.63 times its book value
  • The company has delivered a poor sales growth of 6.32% over past five years.
  • Company has a low return on equity of 10.8% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1612
OscillatorsBullish063
Moving AveragesStrong Bullish109

Key readings

RSI (14)
60.45
Neutral
MACD (12,26,9)
37.43
Bullish
SMA (50)
1,704.58
Bullish
SMA (200)
1,504.03
Bullish

As of

Analyst Rating

Based on 27 analysts
BUY67%

18 of 27 analysts rate Buy, 5 Hold, 4 Sell.

As of

BUY
18
67%
HOLD
5
19%
SELL
4
15%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+9.35%
5Y+6.32%
3Y+10.63%
1Y+6.08%
TTM+13.52%

Net profit

Net profit growth by window
10Y+5.64%
5Y−8.07%
3Y+22.02%
1Y+0.55%
TTM+16.54%

Operating cash flow

Operating cash flow growth by window
10Y+14.55%
5Y+10.67%
3Y+32.29%
1Y+40.79%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−2.77 pp
5Y−0.89 pp
3Y+5.50 pp
1Y−0.27 pp
TTM+0.11 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹14,910 Cr
Mar 2018₹16,463 Cr
Mar 2019₹19,564 Cr
Mar 2020₹23,099 Cr
Mar 2021₹24,775 Cr
Mar 2022₹23,455 Cr
Mar 2023₹24,855 Cr
Mar 2024₹29,002 Cr
Mar 2025₹31,724 Cr
Mar 2026₹33,653 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2,301 Cr
Mar 2018₹2,423 Cr
Mar 2019₹2,364 Cr
Mar 2020₹2,844 Cr
Mar 2021₹5,334 Cr
Mar 2022₹2,647 Cr
Mar 2023₹1,928 Cr
Mar 2024₹3,169 Cr
Mar 2025₹3,484 Cr
Mar 2026₹3,503 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹2,182 Cr −4.5% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk medium

Aurobindo Pharma trades at a market cap of ₹1,03,229 Cr with a PE of 25.98x as of 2026-11-17. The stock has delivered a 45% return over the past one year and is near its 52-week high of ₹1,859.9, while carrying a modest debt-to-equity ratio of 0.21 and showing improved recent profit growth of 19% TTM against a weaker five-year compounded profit growth of just 1%.

Bull Case 8
  • Strong recent stock performance with a 1-year CAGR of 45%, significantly outperforming its 10-year CAGR of 10%
  • TTM sales growth of 14% marks a notable acceleration versus the 5-year compounded sales growth of 6%
  • TTM profit growth of 19% represents a sharp recovery from a muted 1% compounded profit growth over 5 years
  • Conservative balance sheet with a debt-to-equity ratio of just 0.21, providing financial flexibility for future expansion
  • 3-year compounded profit growth of 23% indicates a sustained earnings recovery trend, not a one-off spike
  • 3-year stock CAGR of 21% and 5-year stock CAGR of 23% suggest consistent wealth creation over medium-term horizons
  • 10-year compounded sales growth of 9% demonstrates long-term revenue scaling ability in a competitive generic pharma landscape
  • Current price of ₹1,794.1 is 62% above its 52-week low of ₹1,106, reflecting strong upward momentum over the trailing year
Bear Case 7
  • 5-year compounded sales growth of only 6% indicates a prolonged period of sluggish top-line expansion
  • 3-year average return on equity of roughly 11% and last year ROE of 10% remain below the 10-year average of 14%, suggesting declining capital efficiency
  • Stock trades at 2.62x book value as of 2026-11-17, which is elevated for a company with a current ROE of only 9.25%
  • 5-year compounded profit growth of just 1% highlights that the recent earnings recovery follows years of near-stagnant profitability
  • ROCE of 13.58% and ROE of 9.25% show a meaningful gap, and the company may be capitalizing interest costs which could flatter reported earnings
  • Dividend yield of only 0.39% offers minimal income return to shareholders relative to the PE of 25.98x
  • PE of 25.98x against an EPS of ₹69.05 implies the market is pricing in sustained high growth, which the 5-year profit CAGR of 1% has not historically supported

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9m ago

TL;DR: Aurobindo Pharma delivered a strong Q2FY27 with record revenue of ₹10,263 crore and 32.5% profit growth, beating estimates across all parameters. The key risk is the USFDA OAI classification on a subsidiary facility, though the company says it has no financial or operational impact. The stock is up ~51% in 2026, reflecting strong execution in the US and Europe. With full Lannett integration and biosimilar ramp-up, FY28 outlook appears constructive if regulatory issues remain contained.

Headwinds 1
  • USFDA OAI for subsidiary plant Nov 11

    USFDA issued an OAI classification with 4 observations for a subsidiary's manufacturing facility inspected Aug 17-21, 2026. Shares fell 3% over two sessions, snapping a 12-day winning streak.

Positives 4
  • Q2FY27 profit beats estimates Nov 4

    Consolidated net profit rose 32.5% YoY to ₹1,124-1,126 crore on highest-ever quarterly revenue of ₹10,263 crore (+23.9% YoY). EBITDA jumped 28.5% to ₹2,156 crore with margin expanding 77 bps to 21%.

  • Strong US and Europe growth Nov 4

    US revenue grew 25.2% YoY to ₹4,555 crore and Europe surged 27.5% to ₹3,161 crore. The company received 12 USFDA approvals and launched 10 US products including generic Advair.

  • Robust cash and dividend declared Nov 4

    Free cash flow of $146 million in Q2; net cash position of $189 million as of Sep 30, 2026. Board approved interim dividend of ₹7 per share with Nov 11 record date.

Neutral 5
  • Apitoria Unit-6 gets VAI status Nov 21

    Apitoria Pharma Unit-6 received a VAI classification from USFDA after 3 inspection observations. No regulatory action recommended and inspection is officially closed with EIR received.

  • Shareholder vote on director, pay Nov 18

    Postal ballot initiated for M.R. Kumar's second term as Independent Director and remuneration revisions for top executives effective Nov 1, 2026.

  • API subsidiaries merger approved Nov 4

    Board approved merger of wholly owned subsidiaries Auroactive and Apitoria to consolidate API operations and improve efficiency.

Quarterly Results

₹ Cr
AUROPHARMA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
7,219
7,352
7,580
7,567
7,796
7,979
8,382
7,868
8,286
8,646
8,853
9,150
10,263
Expenses
5,846
5,753
5,920
5,949
6,230
6,401
6,622
6,265
6,608
6,873
7,103
7,271
8,110
Operating Profit
1,373
1,599
1,660
1,618
1,566
1,578
1,760
1,603
1,678
1,773
1,750
1,880
2,153
OPM %
19%
22%
22%
21%
20%
20%
21%
20%
20%
21%
20%
21%
21%
Other Income
188
163
14
221
136
159
135
107
121
123
117
264
168
Interest
68
76
89
111
113
118
115
98
95
93
98
102
102
Depreciation
418
423
354
404
382
419
444
406
429
465
479
487
531
Exceptional Items
—
—
—
—
—
—
—
—
—
—
—
−40.18
—
PBT
1,076
1,262
1,230
1,324
1,207
1,200
1,335
1,207
1,276
1,339
1,291
1,517
1,688
Tax %
30%
26%
26%
31%
32%
30%
32%
32%
34%
32%
29%
32%
33%
Net Profit
752
940
907
918
817
846
903
824
848
910
921
1,032
1,124
EPS (₹)
12.92
15.98
15.51
15.69
14.07
14.56
15.56
14.20
14.61
15.67
15.86
17.95
19.57
YoY Sales growth
26
15
17
10
8
9
11
4
6
8
6
16
24

Profit & Loss

₹ Cr
AUROPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
12,103
13,772
14,910
16,463
19,564
23,099
24,775
23,455
24,855
29,002
31,724
33,653
36,913
Expenses
9,524
10,579
11,469
12,691
15,612
18,249
19,497
19,060
21,148
23,176
25,164
26,783
29,357
Operating Profit
2,579
3,193
3,441
3,772
3,952
4,849
5,278
4,396
3,707
5,826
6,560
6,870
7,556
OPM %
21%
23%
23%
23%
20%
21%
21%
19%
15%
20%
21%
20%
20%
Other Income
81
200
115
105
70
166
3,195
152
291
366
613
404
632
Interest
160
257
67
78
263
305
74
49
140
290
457
384
395
Depreciation
333
392
428
558
668
967
1,055
1,127
1,245
1,522
1,649
1,778
1,961
PBT
2,168
2,744
3,061
3,241
3,091
3,743
7,344
3,373
2,612
4,380
5,066
5,110
5,832
Tax %
28%
26%
25%
25%
24%
24%
27%
22%
26%
28%
31%
31%
—
Net Profit
1,571
2,024
2,301
2,423
2,364
2,844
5,334
2,647
1,928
3,169
3,484
3,503
3,987
EPS (₹)
26.98
34.61
39.29
41.36
40.36
48.56
91.05
45.20
32.90
54.15
60.02
60.34
69.05
Div. Payout %
8%
7%
6%
6%
6%
6%
4%
20%
23%
8%
0%
7%
—
Sales growth
50
14
8
10
19
18
7
−5
6
17
9
6
14

Balance Sheet

₹ Cr
AUROPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
29
59
59
59
59
59
59
59
59
59
58
58
58
Reserves
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
37,833
39,342
Borrowings
4,451
5,041
3,364
4,770
6,967
5,826
5,339
2,851
5,286
6,648
8,263
8,073
8,630
Other Liabilities
3,303
3,568
3,464
4,492
5,414
6,113
6,147
6,211
7,379
8,227
8,566
12,232
13,725
Total Liabilities
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196
61,754
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,396
9,374
10,532
11,024
14,493
14,794
17,407
21,415
CWIP
420
848
1,458
1,583
1,668
1,986
3,062
3,747
5,390
3,869
4,900
5,214
3,487
Investments
20
123
246
312
360
555
591
997
543
372
252
1,051
354
Other Assets
8,765
10,745
9,662
12,527
15,768
16,827
20,390
18,362
22,549
25,983
29,536
34,525
36,498
Total Assets
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196
61,754

Cash Flow

₹ Cr
AUROPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,016
2,387
2,435
3,925
5,526
Investing
−1,017
−1,446
−1,787
−1,927
−2,904
−1,563
597
−3,211
−3,971
−4,242
−1,866
−2,630
Financing
93
365
−1,915
864
1,919
−1,947
−1,365
−2,969
1,814
800
120
−1,269
Net Cash Flow
313
340
−424
892
666
871
2,561
−1,164
230
−1,007
2,178
1,628
Free Cash Flow
491
−146
1,594
714
114
2,969
1,503
2,693
−323
−1,067
1,408
2,468
CFO/EBITDA
67
67
118
70
61
106
87
143
84
72
86
107

Ratios

AUROPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
107
122
68
68
64
68
52
62
66
61
66
77
Inventory Days
239
240
246
317
304
289
333
272
275
284
295
326
Days Payable
136
146
122
128
107
97
103
97
125
129
117
151
Cash Conversion Cycle
210
217
191
257
260
260
282
237
216
216
244
252
Working Capital Days
50
44
51
50
25
35
52
84
55
66
49
44
ROCE %
27%
27%
25%
23%
18%
19%
18%
13%
9%
14%
14%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aurobindo Pharma insights

71 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.88%
  • DIIs 24.42%
  • FIIs 17.41%
  • Public 5.02%
  • Others 1.27%

11.99% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Aurobindo Pharma

What does Aurobindo Pharma Ltd do?
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Where is Aurobindo Pharma Ltd (AUROPHARMA) listed?
Aurobindo Pharma Ltd trades as AUROPHARMA on the NSE and under code 524804 on the BSE.
Which sector does Aurobindo Pharma Ltd belong to?
Aurobindo Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has a market capitalisation of ₹1,03,510 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd trades at a PE ratio of 26.05 as of 20 Nov 2026, on earnings per share of ₹69.05, against a book value of ₹684.77 per share.
What is the 52-week high and low of Aurobindo Pharma Ltd?
Over the last 52 weeks Aurobindo Pharma Ltd has traded between ₹1,106 and ₹1,859.9 as of 20 Nov 2026.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd has a dividend yield of 0.39%.
What is the Return on Equity (ROE) of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd reported a return on equity of 10.10%. Its debt-to-equity ratio is 0.22.

Company Information

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

CEO Mr. Kambam Nithyananda Reddy
Employees 27,707
Listed 6 Apr 1995
Face Value ₹1
Shares Outstanding 57,53,77,895

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AUROPHARMA.md for Aurobindo Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More